News & Analysis on Clinical Trial Services & Contract Research And Development
The combination cholesterol drug Liptruzet will be unavailable in the US for the foreseeable future, says Merck & Co., after packaging defect at CMO led to a total product recall.
Chinese authorities have given Thermo Fisher Scientific the green light to buy Life Technologies on the condition it discounts certain products sold in the coutry.
Subdued demand from Biopharma for its chromatography equipment could be reversed by its benchtop mass spectrometry technology, Waters says.
The six biggest CROs look set to see revenues grow in the next few years with both Parexel and Icon predicting the group will capture a larger share of research spend.
Drugs containing APIs derived from cannabis plants are a far cry from the non-clinical approach of marijuana dispensaries, says GWPharma, as France approves Sativex.
Sanofi has partnered with German contract research organisation (CRO) Fraunhofer-Gesellschaft to search for antibiotics in nature.
World Courier says it is expanding its European ground fleet as pharma and supplier demand grows in the wake of new EU GDP guidelines.
Genentech has resolved the issues that earned its Herceptin API plant in Vacaville, California a Form 483 from the US FDA last year.